Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer. At the same time it will be investigated whether the drug induces side effects, and if so, which ones.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy

NCT00096551

Prostatic Neoplasms

COMPLETED PHASE1

Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154

NCT00535834

Prostate Cancer

COMPLETED

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

NCT00831467

Hormonal Refractory Prostate Cancer

COMPLETED PHASE1/PHASE2

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

NCT02234115

Prostatic Neoplasms

COMPLETED PHASE3

Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy

NCT00006044

Prostate Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prostate cancer growth is influenced by the male hormone testosterone. Treatment with drugs that stop the production of testosterone often results in a decrease of the tumor or inhibition of its growth. This is particularly important prior to radiotherapy, since radiation can better be focused on the prostate with as a result less frequent or less severe side effects of the radiation.

Most of the drugs used to date to stop the production of testosterone have the disadvantage that initially they may cause a rise of testosterone levels before the production is effectively blocked. The new drug that will be investigated in this trial is a vaccine. The vaccine offers a different treatment modality since it interferes at a different level of the hormonal axis that drives the testosterone production; it will not cause an initial surge.

In this trial the vaccine will be administered three times, testosterone levels will be monitored for a total period of three months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PEP-223/CoVaccine HT

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pathological confirmed prostatic adenocarcinoma, clinical stage (c) cT1-3, cN0-1/x, cM0
* baseline testosterone levels of \> 4 nmol/l
* baseline PSA level of \> 10 microg/l
* eligible for hormone therapy
* willingness to comply with the protocol conditions and procedures
* willing and able to give informed consent

Exclusion Criteria

* clinical evidence of distant metastases
* previous hormonal therapy administered specifically for prostatic carcinoma
* development of another invasive neoplastic disease during the previous 5 years, or concomitant presence of another invasive neoplastic disease, except basal cell carcinoma or squamous cell carcinoma of the skin
* primary or secondary immunodeficiency, including immunosuppressive disease or use of corticosteroids or other immunosuppressive medications
* concomitant administration - or administration during the 12 weeks preceding study inclusion - of immune enhancing medication or testosterone supplements
* concomitant radiotherapy for prostate cancer
* presence of bacterial prostatitis causing a PSA increase during the 8 weeks preceding study inclusion
* simultaneous participation in another clinical trial or participation in a clinical trial involving investigational drugs within 3 months before enrollment into the present study
* BMI \> 30 kg/square meter
* previous serious reaction to a vaccine such as angioedema or anaphylaxis

Eligible Sex

MALE

Accepts Healthy Volunteers

No